Treasurer of the State of North Carolina Sells 490 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Treasurer of the State of North Carolina lowered its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 58,123 shares of the biopharmaceutical company’s stock after selling 490 shares during the quarter. Treasurer of the State of North Carolina’s holdings in Regeneron Pharmaceuticals were worth $41,403,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in REGN. MML Investors Services LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 13.9% in the third quarter. MML Investors Services LLC now owns 5,315 shares of the biopharmaceutical company’s stock valued at $5,587,000 after purchasing an additional 648 shares during the period. M&T Bank Corp boosted its stake in shares of Regeneron Pharmaceuticals by 4.3% in the third quarter. M&T Bank Corp now owns 5,480 shares of the biopharmaceutical company’s stock worth $5,761,000 after buying an additional 224 shares during the last quarter. Coldstream Capital Management Inc. boosted its position in Regeneron Pharmaceuticals by 4.8% during the third quarter. Coldstream Capital Management Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $1,359,000 after purchasing an additional 60 shares in the last quarter. Toronto Dominion Bank grew its holdings in shares of Regeneron Pharmaceuticals by 2.6% during the third quarter. Toronto Dominion Bank now owns 54,719 shares of the biopharmaceutical company’s stock worth $57,523,000 after buying an additional 1,378 shares in the last quarter. Finally, Soltis Investment Advisors LLC raised its stake in Regeneron Pharmaceuticals by 4.1% during the third quarter. Soltis Investment Advisors LLC now owns 711 shares of the biopharmaceutical company’s stock worth $747,000 after purchasing an additional 28 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Up 3.6 %

Shares of REGN stock opened at $576.72 on Thursday. The firm has a 50 day moving average price of $665.21 and a two-hundred day moving average price of $762.01. The company has a market capitalization of $63.05 billion, a PE ratio of 15.07, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $525.99 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the previous year, the company posted $11.86 earnings per share. The company’s quarterly revenue was up 10.3% on a year-over-year basis. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.61%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on REGN shares. Wells Fargo & Company lowered their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. Sanford C. Bernstein reduced their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Robert W. Baird cut their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 5th. TD Cowen cut their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. Finally, Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $966.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.